News and Announcements
Investors Can Now Receive 20% Tax Offset on Their Investments
- Published June 19, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
The upcoming ESIC Tax Offset deadlines, as recent media indicates that more attention is needed on this new incentive. As you probably know, if you qualify, you can use this ESIC Tax Offset to your advantage when raising capital.
If you are an Early Stage Innovation Company (ESIC) then the 30th June and 31st July are key dates.
Make sure you check your ESIC eligibility, first of all. You can check out the ATO website, or talk to a consultant to find out (details below).
Getting funds invested and shares issued before June 30 may have a big impact on your investors ability to claim the ESIC benefits.
Then the company must lodge with the ATO by the 31st July.
ESIC Tax Offset Overview
Just over a year ago the government introduced tax incentives for early stage investors whereby from July 1, 2016, if they invest in a qualifying early stage innovation company (ESIC), they may be eligible for tax incentives.
To qualify for the tax incentives, investors must have purchased new shares in a company that meets the requirements of an ESIC immediately after the shares are issued. The shares must have been issued on or after July 1, 2016.
A company will qualify as an ESIC if it meets both:
1) the early stage test; and
2) either the 100-point innovation test or principles-based innovation test.
Review your eligibility and provide investors with a position statement.
By being registered with ESIC your investors get a 20% tax offset of up to $200,000, plus altered CGT status which can reduces CGT to 0%. Sophisticated and professional investors can invest up to $1,000,000, and other investors can invest up to $50,000. There are exclusions to check on for affiliate investors, and investors with over 30% shareholdings.
Support Services
ATO Website:
BIIG Trend is a specialist financial firm, focused on innovation. Biig Trend are assisting with several Wholesale Investor clients with ESIC eligibility assessments, position statements, investor communications, and upcoming lodgements.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
